Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post Authorization Safety Study

INTRODUCTION: Sodium-glucose co-transporter-2 (SGLT2) inhibitors moderately reduce glucose levels in type-2 diabetes mellitus (T2DM). Some cases of diabetic ketoacidosis (DKA) were reported with SGLT2 inhibitors. However, data on the long-term safety of dapagliflozin in Saudi Arabia are lacking. The...

Descripción completa

Detalles Bibliográficos
Autor principal: Alguwaihes, Abdullah M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266941/
https://www.ncbi.nlm.nih.gov/pubmed/34118010
http://dx.doi.org/10.1007/s13300-021-01092-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266941/
https://www.ncbi.nlm.nih.gov/pubmed/34118010
http://dx.doi.org/10.1007/s13300-021-01092-0

Ejemplares similares